Davidson Capital Management Inc. Lowers Stock Position in Halozyme Therapeutics, Inc. $HALO

Davidson Capital Management Inc. cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 56,031 shares of the biopharmaceutical company’s stock after selling 5,187 shares during the period. Davidson Capital Management Inc.’s holdings in Halozyme Therapeutics were worth $2,915,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of HALO. Alliancebernstein L.P. boosted its position in Halozyme Therapeutics by 4.8% during the 1st quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company’s stock valued at $205,156,000 after acquiring an additional 146,677 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Halozyme Therapeutics by 4.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company’s stock worth $129,478,000 after purchasing an additional 95,600 shares during the last quarter. TD Asset Management Inc boosted its position in Halozyme Therapeutics by 5.8% during the first quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company’s stock valued at $92,642,000 after purchasing an additional 79,708 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its position in Halozyme Therapeutics by 27.3% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock valued at $72,107,000 after purchasing an additional 242,167 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its stake in Halozyme Therapeutics by 951.8% in the second quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company’s stock valued at $50,650,000 after purchasing an additional 881,094 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $75.24, for a total value of $150,480.00. Following the sale, the director owned 44,952 shares in the company, valued at $3,382,188.48. This represents a 4.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at $50,648,622.57. This represents a 2.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 88,227 shares of company stock valued at $6,509,395 over the last quarter. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $68.01 on Tuesday. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The company’s fifty day moving average price is $70.56 and its 200-day moving average price is $62.95. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $79.50. The firm has a market capitalization of $8.00 billion, a PE ratio of 15.56, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million during the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm’s quarterly revenue was up 22.1% on a year-over-year basis. During the same quarter last year, the business posted $1.27 EPS. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Zacks Research lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research note on Monday, October 20th. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 6th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, October 21st. Finally, Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Seven investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $75.00.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.